CN1922175A - 作为5－ht4受体激动剂的吲唑－甲酰胺化合物 - Google Patents

作为5－ht4受体激动剂的吲唑－甲酰胺化合物 Download PDF

Info

Publication number
CN1922175A
CN1922175A CNA200580005307XA CN200580005307A CN1922175A CN 1922175 A CN1922175 A CN 1922175A CN A200580005307X A CNA200580005307X A CN A200580005307XA CN 200580005307 A CN200580005307 A CN 200580005307A CN 1922175 A CN1922175 A CN 1922175A
Authority
CN
China
Prior art keywords
indazole
carboxylic acid
oct
ethyl
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200580005307XA
Other languages
English (en)
Chinese (zh)
Inventor
D·马克斯
崔锡基
P·R·法瑟里
R·让德龙
A·A·戈德布卢姆
D·D·隆
S·D·特纳
刘健伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiwan Pharmaceutical
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1922175(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Publication of CN1922175A publication Critical patent/CN1922175A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA200580005307XA 2004-02-18 2005-02-17 作为5－ht4受体激动剂的吲唑－甲酰胺化合物 Pending CN1922175A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54570204P 2004-02-18 2004-02-18
US60/545,702 2004-02-18

Publications (1)

Publication Number Publication Date
CN1922175A true CN1922175A (zh) 2007-02-28

Family

ID=34886184

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200580005307XA Pending CN1922175A (zh) 2004-02-18 2005-02-17 作为5－ht4受体激动剂的吲唑－甲酰胺化合物

Country Status (16)

Country Link
US (3) US7351704B2 (enExample)
EP (1) EP1718643A1 (enExample)
JP (1) JP2007523175A (enExample)
KR (1) KR20060132727A (enExample)
CN (1) CN1922175A (enExample)
AR (1) AR047681A1 (enExample)
AU (1) AU2005214368A1 (enExample)
BR (1) BRPI0507791A (enExample)
CA (1) CA2553696A1 (enExample)
IL (1) IL177059A0 (enExample)
MA (1) MA28435B1 (enExample)
NO (1) NO20064156L (enExample)
RU (1) RU2006133320A (enExample)
TW (1) TW200533348A (enExample)
WO (1) WO2005080389A1 (enExample)
ZA (1) ZA200606479B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604921A (zh) * 2014-08-16 2017-04-26 苏文生命科学有限公司 用于大规模生产1‑异丙基‑3‑{5‑[1‑(3‑甲氧基丙基)哌啶‑4‑基]‑[1,3,4]噁二唑‑2‑基}‑1h‑吲唑草酸盐的方法
WO2021046789A1 (zh) * 2019-09-12 2021-03-18 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE431824T1 (de) * 2004-11-05 2009-06-15 Theravance Inc Chinolinon-carboxamid-verbindungen
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
WO2006069125A1 (en) * 2004-12-22 2006-06-29 Theravance, Inc. Indazole-carboxamide compounds
JP2008530225A (ja) * 2005-02-17 2008-08-07 セラヴァンス， インコーポレーテッド インダゾール−カルボキサミド化合物の結晶型
WO2006094063A1 (en) * 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-ht4 receptor agonists
ATE495171T1 (de) * 2005-06-07 2011-01-15 Theravance Inc Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
WO2007102883A2 (en) * 2005-10-25 2007-09-13 Smithkline Beecham Corporation Chemical compounds
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
ATE509021T1 (de) * 2006-02-16 2011-05-15 Theravance Inc Verfahren zur herstellung von zwischenverbindungen zu 5-ht4-rezeptoragonist- verbindungen
KR100812499B1 (ko) * 2006-10-16 2008-03-11 이도훈 항경련제
WO2008101728A1 (de) * 2007-02-23 2008-08-28 K.H.S. Pharma Holding Gmbh Verfahren zur herstellung von azoniaspironortropinestern und von nortropan-3-on verbindungen
KR20100124262A (ko) * 2008-02-13 2010-11-26 에자이 알앤드디 매니지먼트 가부시키가이샤 비시클로아민 유도체
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
WO2011099305A1 (en) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
WO2012169649A1 (en) * 2011-06-07 2012-12-13 Dainippon Sumitomo Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
CN104271579A (zh) 2012-05-03 2015-01-07 诺华股份有限公司 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶
JP2014133739A (ja) * 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321378A (en) * 1979-01-16 1982-03-23 Delalande S.A. 8-(5-Pyrimidinecarboxamide)nor-tropane derivatives
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
HU202108B (en) * 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
IT1231413B (it) 1987-09-23 1991-12-04 Angeli Inst Spa Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
IT1226389B (it) * 1988-07-12 1991-01-15 Angeli Inst Spa Nuovi derivati ammidinici e guanidinici
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
EP0410509A1 (en) * 1989-07-25 1991-01-30 Duphar International Research B.V New substituted 1H-indazole-3-carboxamides
JPH045289A (ja) 1990-04-24 1992-01-09 Hokuriku Seiyaku Co Ltd アミド化合物
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
CA2097815C (en) * 1990-12-28 2001-04-17 Fumio Suzuki Quinoline derivative
PT100785A (pt) 1991-08-20 1994-04-29 Smithkline Beecham Plc Utilizacao de compostos, por exemplo indole-3-carboxilatos, para a producao de medicamentos, compostos ai utilizados e composicoes farmaceuticas que os contem.
CA2118798A1 (en) * 1991-09-12 1993-03-18 Francis D. King Azabicyclic compounds as 5-ht4 receptor antagonists
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
TW251287B (enExample) 1993-04-30 1995-07-11 Nissei Co Ltd
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
WO1995023147A1 (en) * 1994-02-28 1995-08-31 Taisho Pharmaceutical Co., Ltd. Heterocyclic compound
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
GB9406857D0 (en) * 1994-04-07 1994-06-01 Sandoz Ltd Improvements in or relating to organic compounds
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
CA2160420A1 (en) * 1994-10-20 1996-04-21 Haruhiko Kikuchi 5-ht4 receptor agonists
JP3829880B2 (ja) 1994-12-27 2006-10-04 大正製薬株式会社 化学中間体
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
WO1996038420A1 (en) * 1995-05-31 1996-12-05 Nisshin Flour Milling Co., Ltd. Indazole derivatives having monocyclic amino group
ES2109190B1 (es) 1996-03-22 1998-07-01 Univ Madrid Complutense Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US5914405A (en) * 1997-10-07 1999-06-22 Eli Lilly And Company Process for preparing 3-substituted indazoles
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2769915B1 (fr) 1997-10-21 2000-10-13 Synthelabo Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
IT1298271B1 (it) 1998-02-18 1999-12-20 Boehringer Ingelheim Italia Esteri ed ammidi dell'acido 2-oxo-2,3-diidro-benzimidazol-1- carbossilico
EP1076055B1 (en) * 1998-04-28 2004-11-24 Dainippon Pharmaceutical Co., Ltd. 1- (1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
KR100413150B1 (ko) * 1998-09-10 2003-12-31 에프. 호프만-라 로슈 아게 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
FR2792318B1 (fr) 1999-04-16 2001-06-15 Synthelabo Derives d'indazole, leur preparation et leur application en therapeutique
EP1173168A2 (en) * 1999-04-28 2002-01-23 Respiratorius AB Compound for use as a medicament for treatment of disorders involving bronchocontraction
ES2154605B1 (es) 1999-09-14 2001-11-16 Univ Madrid Complutense Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
IT1313660B1 (it) 1999-10-01 2002-09-09 Dompe Spa Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.
WO2002036113A1 (en) 2000-11-01 2002-05-10 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
BR0309118A (pt) 2002-04-08 2005-02-01 Pfizer Derivados de tropano úteis em terapêutica
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
JP2006502180A (ja) * 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
BRPI0409592A (pt) * 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
JO2478B1 (en) 2003-06-19 2009-01-20 جانسين فارماسوتيكا ان. في. (Aminomethyl) -biperidine benzamides as 5 HT4 antagonists
US7652040B2 (en) 2003-06-19 2010-01-26 Janssen Pharmaceutica N.V. Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists
DK1664036T3 (da) 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
EP1713797B1 (en) 2004-01-29 2008-03-05 Pfizer, Inc. 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106604921A (zh) * 2014-08-16 2017-04-26 苏文生命科学有限公司 用于大规模生产1‑异丙基‑3‑{5‑[1‑(3‑甲氧基丙基)哌啶‑4‑基]‑[1,3,4]噁二唑‑2‑基}‑1h‑吲唑草酸盐的方法
CN106604921B (zh) * 2014-08-16 2019-04-02 苏文生命科学有限公司 大规模生产1-异丙基-3-{5-[1-(3-甲氧基丙基)哌啶-4-基]-[1，3，4]噁二唑-2-基}-1h-吲唑草酸盐的方法
WO2021046789A1 (zh) * 2019-09-12 2021-03-18 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途
CN112805282A (zh) * 2019-09-12 2021-05-14 广东东阳光药业有限公司 吲唑-甲酰胺衍生物及其用途

Also Published As

Publication number Publication date
RU2006133320A (ru) 2008-03-27
JP2007523175A (ja) 2007-08-16
US7674908B2 (en) 2010-03-09
AR047681A1 (es) 2006-02-01
US7351704B2 (en) 2008-04-01
US20080146807A1 (en) 2008-06-19
ZA200606479B (en) 2008-01-30
MA28435B1 (fr) 2007-02-01
KR20060132727A (ko) 2006-12-21
US20050197335A1 (en) 2005-09-08
TW200533348A (en) 2005-10-16
AU2005214368A1 (en) 2005-09-01
EP1718643A1 (en) 2006-11-08
NO20064156L (no) 2006-11-10
US8044045B2 (en) 2011-10-25
CA2553696A1 (en) 2005-09-01
BRPI0507791A (pt) 2007-07-17
IL177059A0 (en) 2006-12-10
WO2005080389A1 (en) 2005-09-01
US20100261716A1 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
CN1922175A (zh) 作为5－ht4受体激动剂的吲唑－甲酰胺化合物
CN101080406A (zh) 吲唑－甲酰胺化合物
US7498442B2 (en) Quinolinone-carboxamide compounds
US7534889B2 (en) 5-HT4 receptor agonist compounds
CN1946719A (zh) 作为5－ht4受体激动剂的喹啉酮－甲酰胺化合物
HK1039902A1 (zh) 用作趋化因子受体5调节剂的氮杂二环烷烃
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
US20090036483A1 (en) Quinolinone compounds as 5-ht4 receptor agonists
CN1252068C (zh) 作为伤害感受蛋白受体orl－1优良配体的杂芳基衍生物
US8143279B2 (en) Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
US7851467B2 (en) Carbamate compounds as 5-HT4 receptor agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned